華瑞股份(300626.SZ)擬1.95億元購買康澤藥業15%股份
格隆匯1月26日丨華瑞股份(300626.SZ)公佈,公司於2021年1月26日召開第三屆董事會第十四次會議,審議通過了《關於公司對外投資的議案》,公司將以現金方式購買康澤藥業股份有限公司(“康澤藥業”)3937.14萬股股份(約佔康澤藥業總股本的15.00%),標的股份的每股單價為4.95元,轉讓價格合計為人民幣約1.95億元。同日,公司與陳齊黛、廣東良濟堂投資有限公司簽署了《股權轉讓協議》。
康澤藥業是涵蓋醫藥流通全產業鏈的一站式綜合性醫藥分銷企業,主營業務包括醫藥電商批發(B2B)、醫藥電商零售(B2C)、醫藥零售連鎖和醫藥線下批發。康澤藥業的主要服務對象為藥品分銷企業、連鎖藥店、單體藥店、非跟標醫療機構和個人消費者,致力於各業務板塊的協同發展,以不斷擴大服務對象、提高服務效率,從而提高綜合競爭力,保障持續健康發展,主要利潤來自商品進銷差價和諮詢推廣服務收入。該公司是粵東連鎖藥店龍頭企業,在廣東省醫藥流通領域具有重要的行業地位。該公司銷售的產品以處方藥為主,而且慢病處方藥、外資藥佔比較高,尤其是外資藥品品種齊全,上游廠商資源十分豐富。康澤藥業的藥品銷售主要面向零售終端,而不是公立醫院,隨着我國以“醫藥分家”為核心的醫改政策的推行,醫藥零售終端在我國醫藥流通佔有的市場份額逐步提升,康澤藥業未來幾年面臨着較好的發展機遇。
公司自設立以來專注於從事小功率電機和微特電機換向器的研發、設計、生產和銷售,公司轉向器產品市場佔有率保持在全球前三,未來,公司在鞏固轉向器市場地位的同時亟需尋找新的利潤增長點。2020年,公司控股股東變更為梧州市城建投資發展集團有限公司下屬的梧州市東泰國有資產經營有限公司,梧州市城建投資發展集團有限公司是梧州市最大的國有企業,而醫藥產業是梧州市的支柱性產業之一。經公司控股股東建議,並經公司董事會審慎研究、討論,公司將逐步發展醫藥產業,培育公司主營業務和利潤新的增長點。此次公司戰略投資康澤藥業是公司進軍醫藥領域的第一步嘗試,有利於提升公司持續經營能力和公司長遠發展,符合公司及全體股東的根本利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.